![Natalie Holles](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Natalie Holles
Amministratore Delegato presso
AURA BIOSCIENCES, INC.
Patrimonio netto: 9 M $ in data 31/05/2026
Profilo
Natalie C.
Holles is President, Chief Executive Officer & Director at Aura Biosciences, Inc. since 2026.
Ms. Holles is Director at LeonaBio, Inc. since 2026.
Ms. Holles is Director at DOT Therapeutics-2, Inc. since 2021.
Formerly, Ms. Holles was President, Chief Executive Officer & Director at Astellas Gene Therapies, Inc. from 2020 to 2021.
Ms. Holles was Chief Executive Officer & Director at Third Harmonic Bio, Inc. from 2021 to 2025.
Ms. Holles was Independent Director at Allakos, Inc. from 2020 to 2021.
Ms. Holles was Independent Director at Rubius Therapeutics, Inc. from 2019 to 2022.
Ms. Holles was Independent Director at Day.
One Biopharmaceuticals, Inc. from 2022 to 2026.
Ms. Holles was Principal at InterMune, Inc. Ms. Holles was Vice President-Business Development at KAI Pharmaceuticals, Inc. from 2005 to 2010.
Ms. Holles was Senior VP-Corporate & Business Development at Hyperion Therapeutics, Inc. from 2013 to 2015.
Ms. Holles was Executive Vice President-Corporate Development at Immune Design Corp.
from 2012 to 2013.
Ms. Holles was Head-Business Development at Genentech, Inc. from 1999 to 2000.
Education includes undergraduate degree from Stanford University and graduate degree from the University of Colorado Boulder.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
AURA BIOSCIENCES INC 1,86% | 19/05/2026 | 1.153.962 ( 1,86% ) | 9 M $ | 31/05/2026 |
LEONABIO, INC. -.--% | 23/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Posizioni attive di Natalie Holles
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Amministratore Delegato | 30/04/2026 |
| LEONABIO, INC. | Direttore/Membro del Consiglio | 05/05/2026 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Direttore/Membro del Consiglio | 17/02/2021 |
Precedenti posizioni note di Natalie Holles
| Società | Posizione | Fine |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 23/04/2026 |
| THIRD HARMONIC BIO, INC. | Amministratore Delegato | 01/12/2025 |
| RUBIUS THERAPEUTICS | Direttore/Membro del Consiglio | 09/08/2022 |
| ALLAKOS INC. | Direttore/Membro del Consiglio | 06/08/2021 |
| AUDENTES THERAPEUTICS, INC. | Amministratore Delegato | 01/03/2021 |
Formazione di Natalie Holles
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
57
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical drugs | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
LeonaBio, Inc.
 LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
University of Colorado Boulder
 University of Colorado Boulder Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drugs | Health Technology |
Third Harmonic Bio, Inc.
 Third Harmonic Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of allergic and immune diseases and disorders | Health Technology |
Day One Biopharmaceuticals, Inc.
 Day One Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops and commercializes targeted therapies for cancers | Health Technology |
